DK4129330T5 - Sammensætninger og fremgangsmåder til kimære dengue virus-konstruktioner i vacciner - Google Patents

Sammensætninger og fremgangsmåder til kimære dengue virus-konstruktioner i vacciner Download PDF

Info

Publication number
DK4129330T5
DK4129330T5 DK22182269.5T DK22182269T DK4129330T5 DK 4129330 T5 DK4129330 T5 DK 4129330T5 DK 22182269 T DK22182269 T DK 22182269T DK 4129330 T5 DK4129330 T5 DK 4129330T5
Authority
DK
Denmark
Prior art keywords
vaccines
compositions
methods
dengue virus
chimeric dengue
Prior art date
Application number
DK22182269.5T
Other languages
Danish (da)
English (en)
Other versions
DK4129330T3 (da
Inventor
Dan T Stinchcomb
Claire Kinney
Richard M Kinney
Jill A Livengood
Original Assignee
Takeda Vaccines Inc
Us Gov Health & Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc, Us Gov Health & Human Services filed Critical Takeda Vaccines Inc
Publication of DK4129330T3 publication Critical patent/DK4129330T3/da
Application granted granted Critical
Publication of DK4129330T5 publication Critical patent/DK4129330T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK22182269.5T 2013-03-15 2014-03-12 Sammensætninger og fremgangsmåder til kimære dengue virus-konstruktioner i vacciner DK4129330T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361800204P 2013-03-15 2013-03-15
EP20154012.7A EP3689374B1 (en) 2013-03-15 2014-03-12 Compositions and methods for dengue virus chimeric constructs in vaccines

Publications (2)

Publication Number Publication Date
DK4129330T3 DK4129330T3 (da) 2023-12-11
DK4129330T5 true DK4129330T5 (da) 2024-07-22

Family

ID=50678274

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22182269.5T DK4129330T5 (da) 2013-03-15 2014-03-12 Sammensætninger og fremgangsmåder til kimære dengue virus-konstruktioner i vacciner

Country Status (32)

Country Link
US (6) US9783579B2 (enExample)
EP (5) EP3539565B1 (enExample)
JP (2) JP6818548B2 (enExample)
KR (4) KR102389908B1 (enExample)
CN (5) CN111778263B (enExample)
AR (4) AR095598A1 (enExample)
AU (2) AU2014235476B2 (enExample)
CA (4) CA3166063A1 (enExample)
CR (1) CR20150569A (enExample)
DK (1) DK4129330T5 (enExample)
DO (1) DOP2015000232A (enExample)
EC (1) ECSP23013715A (enExample)
ES (2) ES2965652T3 (enExample)
FI (2) FI3539565T3 (enExample)
FR (1) FR22C1064I2 (enExample)
HR (1) HRP20231581T1 (enExample)
HU (2) HUE061507T2 (enExample)
LT (2) LT4129330T (enExample)
MX (5) MX374519B (enExample)
MY (1) MY187796A (enExample)
NL (1) NL301223I2 (enExample)
NO (1) NO2023026I1 (enExample)
NZ (1) NZ630869A (enExample)
PE (2) PE20160027A1 (enExample)
PH (1) PH12015502120B1 (enExample)
PL (1) PL3539565T3 (enExample)
PT (1) PT3539565T (enExample)
SG (3) SG10201913435TA (enExample)
SI (1) SI4129330T1 (enExample)
TW (3) TWI726312B (enExample)
UY (1) UY35489A (enExample)
WO (1) WO2014150939A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102389908B1 (ko) * 2013-03-15 2022-04-26 다케다 백신즈 인코포레이티드 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
MY194650A (en) * 2015-11-27 2022-12-09 Km Biologics Co Ltd Multivalent dengue vaccine composition comprising a mixture of attenuated dengue viruses from different serotypes
KR102611235B1 (ko) * 2016-04-13 2023-12-08 다케다 백신즈 인코포레이티드 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
ES2908304T3 (es) 2018-09-05 2022-04-28 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administración de la misma
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2021173597A1 (en) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dengue serotype specific rt-pcr multiplex assay
EP3892737A1 (en) * 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Qualitative and quantitative determination of single virus haplotypes in complex samples
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024086681A1 (en) * 2022-10-20 2024-04-25 Takeda Vaccines, Inc. A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype
EP4375381A1 (en) 2022-11-18 2024-05-29 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
EP4626574A1 (en) 2022-11-29 2025-10-08 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276941A (en) 1975-12-23 1977-06-28 Ito Masato Method of conversing infrared rays
US4810092A (en) 1986-02-21 1989-03-07 Midac Corporation Economical spectrometer unit having simplified structure
JPH0768267B2 (ja) 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
ATE310824T1 (de) 1991-09-19 2005-12-15 Chimäre und/oder wachstumsgehemmte flaviviren
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
CA2224724C (en) 1995-05-24 2007-12-04 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
ES2244050T3 (es) 1997-02-28 2005-12-01 Acambis Inc. Vacunas quimericas de flavivirus.
WO1999018216A2 (en) 1997-10-08 1999-04-15 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric vaccine against tick-borne encephalitis virus
DE29810020U1 (de) 1998-06-04 1998-09-24 Siemens AG, 80333 München Kunststoffbehälter zur Tieftemperaturlagerung von biologischen Materialien
AU778988B2 (en) 1998-06-04 2004-12-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleic acid vaccines for prevention of flavivirus infection
WO2001039802A1 (en) * 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
WO2001060847A2 (en) * 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
AU2002309508A1 (en) 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides
MX2007015872A (es) * 2005-06-17 2008-04-21 Sanofi Pasteur Cepa atenuada del serotipo 2 del dengue.
CA2611934C (en) * 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
KR20070017759A (ko) 2005-08-08 2007-02-13 삼성전자주식회사 초해상 정보 저장 매체, 기록/재생 장치 및 기록/재생 방법
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
EP2589602B1 (en) * 2006-08-15 2016-04-06 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Development of dengue virus vaccine components
WO2009048658A2 (en) 2007-07-13 2009-04-16 Florida Gulf Coast University Optimized dengue virus entry inhibitory peptide (dn81)
US8715689B2 (en) * 2008-04-30 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
SG157244A1 (en) 2008-05-15 2009-12-29 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure or immunity to dengue virus
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
WO2013188315A1 (en) 2012-06-10 2013-12-19 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
CN102449172A (zh) 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法
CN101560520A (zh) * 2009-06-04 2009-10-21 中国疾病预防控制中心病毒病预防控制所 乙脑/登革嵌合病毒及其应用
BRPI0904020B8 (pt) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
TW201428101A (zh) 2012-11-08 2014-07-16 Inviragen Inc 登革熱病毒血清型４型之建構物的組成物、方法及用途
WO2014093182A1 (en) * 2012-12-14 2014-06-19 Inviragen, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
KR102389908B1 (ko) 2013-03-15 2022-04-26 다케다 백신즈 인코포레이티드 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2017005654A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
KR102611235B1 (ko) 2016-04-13 2023-12-08 다케다 백신즈 인코포레이티드 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
GEP20237575B (en) 2017-10-16 2023-12-25 Serum Institute Of India Pvt Ltd Stable vaccine compositions comprising inter alia live attenuated recombinant dengue virus and process for preparation thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
ES2908304T3 (es) 2018-09-05 2022-04-28 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administración de la misma
EP3892737A1 (en) 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Qualitative and quantitative determination of single virus haplotypes in complex samples

Also Published As

Publication number Publication date
EP2968516B1 (en) 2022-01-12
US11931399B2 (en) 2024-03-19
TWI894248B (zh) 2025-08-21
ES2933970T3 (es) 2023-02-15
KR102626270B1 (ko) 2024-01-19
CA3177572A1 (en) 2014-09-25
AU2014235476B2 (en) 2019-05-16
UY35489A (es) 2014-10-31
MY187796A (en) 2021-10-24
DOP2015000232A (es) 2016-02-29
EP3539565A1 (en) 2019-09-18
NZ630869A (en) 2017-11-24
PE20211814A1 (es) 2021-09-14
CN105451763A (zh) 2016-03-30
BR112015023635A8 (pt) 2021-12-14
BR122021015502A2 (pt) 2021-12-14
CN113637693A (zh) 2021-11-12
NL301223I2 (nl) 2023-07-26
SG10201913387XA (en) 2020-02-27
CN105451763B (zh) 2021-06-18
MX2015012893A (es) 2016-04-04
BR122021015503A2 (pt) 2021-12-14
MX2019003602A (es) 2022-06-27
MX374519B (es) 2025-03-06
PL3539565T3 (pl) 2023-09-25
CR20150569A (es) 2016-04-01
KR20160002780A (ko) 2016-01-08
EP4183411A1 (en) 2023-05-24
TW201516147A (zh) 2015-05-01
CN113637086B (zh) 2024-10-11
WO2014150939A3 (en) 2014-12-31
CA2903231A1 (en) 2014-09-25
US10449231B2 (en) 2019-10-22
AR133264A2 (es) 2025-09-10
US20140302088A1 (en) 2014-10-09
TWI726312B (zh) 2021-05-01
EP3689374B1 (en) 2022-11-02
AR123702A2 (es) 2023-01-04
KR102389908B1 (ko) 2022-04-26
AU2014235476A1 (en) 2015-09-24
JP6818548B2 (ja) 2021-01-20
BR112015023635A2 (pt) 2018-06-05
FI3539565T3 (fi) 2023-04-19
KR20220054892A (ko) 2022-05-03
ES2965652T3 (es) 2024-04-16
FR22C1064I1 (fr) 2023-02-03
US20220062375A1 (en) 2022-03-03
SG11201507460PA (en) 2015-10-29
CN113637693B (zh) 2024-10-11
TWI733646B (zh) 2021-07-21
CN113637086A (zh) 2021-11-12
DK4129330T3 (da) 2023-12-11
NZ735336A (en) 2021-04-30
US20200061151A1 (en) 2020-02-27
AU2019216724B2 (en) 2021-03-04
CA3177574A1 (en) 2014-09-25
EP4129330A1 (en) 2023-02-08
US20230181682A1 (en) 2023-06-15
MX2023000354A (es) 2023-02-13
JP2019146594A (ja) 2019-09-05
MX2023000349A (es) 2023-04-24
JP7050031B2 (ja) 2022-04-07
AR095598A1 (es) 2015-10-28
LTPA2024503I1 (enExample) 2024-03-25
AU2019216724C1 (en) 2021-08-26
CN113637694B (zh) 2024-11-12
EP2968516A2 (en) 2016-01-20
EP3539565B1 (en) 2023-01-11
PH12015502120A1 (en) 2016-01-25
HK1220359A1 (zh) 2017-05-05
MX2023000353A (es) 2023-02-13
US20170290884A1 (en) 2017-10-12
PT3539565T (pt) 2023-04-12
HUS2300022I1 (hu) 2023-08-28
CN113637694A (zh) 2021-11-12
KR20240014580A (ko) 2024-02-01
FIC20230021I1 (fi) 2023-06-27
NO2023026I1 (no) 2023-07-04
TW202144573A (zh) 2021-12-01
EP3689374A1 (en) 2020-08-05
HUE061507T2 (hu) 2023-07-28
PE20160027A1 (es) 2016-01-28
CN111778263A (zh) 2020-10-16
KR20250033325A (ko) 2025-03-07
AR132009A2 (es) 2025-05-21
CA3166063A1 (en) 2014-09-25
FR22C1064I2 (fr) 2024-12-13
LT4129330T (lt) 2023-12-27
US20250018006A1 (en) 2025-01-16
EP4129330B1 (en) 2023-09-06
KR102775714B1 (ko) 2025-03-06
US9783579B2 (en) 2017-10-10
SI4129330T1 (sl) 2024-02-29
CN111778263B (zh) 2024-07-26
HRP20231581T1 (hr) 2024-03-15
WO2014150939A2 (en) 2014-09-25
AU2019216724A1 (en) 2019-09-05
TW201945545A (zh) 2019-12-01
JP2016513970A (ja) 2016-05-19
SG10201913435TA (en) 2020-03-30
ECSP23013715A (es) 2023-04-28
PH12015502120B1 (en) 2024-02-16
US12186363B2 (en) 2025-01-07

Similar Documents

Publication Publication Date Title
DK4129330T3 (da) Sammensætninger og fremgangsmåder til kimære dengue virus-konstruktioner i vacciner
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3080274T3 (da) Fremgangsmåder og sammensætninger til genom-manipulation
DK3441468T3 (da) Afgivelsesfremgangsmåder og sammensætninger til nukleasemedieret genom-manipulation
DK2981822T3 (da) Sammensætninger og fremgangsmåder til vækstfaktormodulation
DK2943078T3 (da) Fremgangsmåder og sammensætninger til føde- og drikkevarer
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK3019533T3 (da) Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf
DK3019200T3 (da) Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf
DK3578201T3 (da) Fremgangsmåder og sammensætninger til naturlige dræberceller
DK3137506T5 (da) Sammensætninger og fremgangsmåder relateret til genmanipulerede fc-konstrukter
BR112015028459A2 (pt) composições e comestíveis
SG11201606624WA (en) Antibody moleules to dengue virus and uses thereof
DK3065771T3 (da) Fremgangsmåder og sammensætninger til vedvarende immunterapi
DK2955996T3 (da) Kultiveringsbundsystem og fremgangsmåde til dets anvendelse
DK3102189T3 (da) Sammensætning og fremgangsmåde til at fremme søvn
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK3011041T3 (da) Biodieselsammensætning og dermed forbundet fremgangsmåde og produkter
PT3043639T (pt) Aparelho para injetar seletivamente ovos, e método associado
HUE053033T2 (hu) Hidrolázoknak ellenálló kapszidokat alkalmazó készítmények és eljárások
DK3024428T3 (da) Sammensætninger og fremgangsmåder til dental mineralisering
DK2968479T3 (da) Terapeutiske sure ceramidasesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
DK2896694T3 (da) Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf
DK2969005T3 (da) Attenuerede influenzavira og -vacciner
SG11201703366RA (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development